2023 Q4 Form 10-Q Financial Statement

#000168316824000170 Filed on January 10, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $2.000K $750.00 $1.350K
YoY Change 300.0%
Cost Of Revenue $0.00
YoY Change
Gross Profit $750.00
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $4.430K $4.330K $11.23K
YoY Change -25.8% -27.1%
% of Gross Profit 577.33%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $670.00 $660.00 $670.00
YoY Change 0.0% -50.38%
% of Gross Profit 88.0%
Operating Expenses $4.425K $4.326K $11.23K
YoY Change -25.82% -27.21% 7.76%
Operating Profit -$2.425K -$3.576K -$9.877K
YoY Change -55.63% -39.83% -5.2%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.430K -$3.580K -$9.880K
YoY Change -55.54% -39.76%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.425K -$3.576K -$9.877K
YoY Change -55.63% -39.83% -5.2%
Net Earnings / Revenue -121.25% -476.8% -731.63%
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.235M shares 3.235M shares 3.235M shares
Diluted Shares Outstanding 3.235M shares 3.235M shares 3.235M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.910K $1.660K $2.660K
YoY Change 151.32% -58.08%
Cash & Equivalents $1.912K $1.661K $2.660K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.912K $1.661K $2.660K
YoY Change 151.58% -58.04%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.664K $2.331K $2.998K
YoY Change -61.59% -53.37%
TOTAL ASSETS
Total Short-Term Assets $1.912K $1.661K $2.660K
Total Long-Term Assets $1.664K $2.331K $2.998K
Total Assets $3.576K $3.992K $5.658K
YoY Change -29.77% -55.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.00K $24.50K $23.00K
YoY Change 30.0% 32.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $18.46K $17.95K $17.54K
YoY Change 184.88% 181.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.46K $42.45K $40.54K
YoY Change 67.91% 70.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $44.46K $42.45K $40.54K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $44.46K $42.45K $40.54K
YoY Change 67.9% 70.62%
SHAREHOLDERS EQUITY
Retained Earnings -$65.78K -$63.36K -$59.78K
YoY Change 42.13% 55.21%
Common Stock $324.00 $324.00 $324.00
YoY Change 0.31% 0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$40.88K -$38.46K -$34.88K
YoY Change
Total Liabilities & Shareholders Equity $3.576K $3.992K $5.658K
YoY Change -29.77% -55.44%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.425K -$3.576K -$9.877K
YoY Change -55.63% -39.83% -5.2%
Depreciation, Depletion And Amortization $670.00 $660.00 $670.00
YoY Change 0.0% -50.38%
Cash From Operating Activities -$260.00 -$1.410K -$7.710K
YoY Change -92.12% -88.28% -6.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 510.0 410.0 $8.560K
YoY Change 410.0% 192.86%
NET CHANGE
Cash From Operating Activities -260.0 -1.410K -$7.710K
Cash From Investing Activities
Cash From Financing Activities 510.0 410.0 $8.560K
Net Change In Cash 250.0 -1.000K $850.00
YoY Change -107.81% -91.59% -110.3%
FREE CASH FLOW
Cash From Operating Activities -$260.00 -$1.410K -$7.710K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001852536
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-255055
dei Entity Registrant Name
EntityRegistrantName
Intorio, Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1578603
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Alexander Kazbegi Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Tblisi
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
0177
dei Entity Address Country
EntityAddressCountry
GE
dei City Area Code
CityAreaCode
(702)
dei Local Phone Number
LocalPhoneNumber
605-4636
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3235000 shares
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1912 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1810 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1912 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1810 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7336 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5335 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1664 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
3665 usd
CY2023Q4 us-gaap Assets
Assets
3576 usd
CY2023Q1 us-gaap Assets
Assets
5475 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
26000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
21500 usd
CY2023Q4 NONE Due To Related Parties Current1
DueToRelatedPartiesCurrent1
18459 usd
CY2023Q1 NONE Due To Related Parties Current1
DueToRelatedPartiesCurrent1
8981 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44459 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30481 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
324 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
324 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24577 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24577 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65784 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49906 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-40883 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-25006 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3576 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5475 usd
CY2023Q4 us-gaap Revenues
Revenues
2000 usd
CY2022Q4 us-gaap Revenues
Revenues
500 usd
us-gaap Revenues
Revenues
4100 usd
us-gaap Revenues
Revenues
500 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4425 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5965 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19978 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22327 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
4425 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5965 usd
us-gaap Operating Expenses
OperatingExpenses
19978 usd
us-gaap Operating Expenses
OperatingExpenses
22327 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2425 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5465 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15878 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-21827 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-2425 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-5465 usd
us-gaap Profit Loss
ProfitLoss
-15878 usd
us-gaap Profit Loss
ProfitLoss
-21827 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-2425 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5465 usd
us-gaap Net Income Loss
NetIncomeLoss
-15878 usd
us-gaap Net Income Loss
NetIncomeLoss
-21827 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
441 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10419 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-9978 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5943 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-15921 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5465 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-21386 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-25006 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9877 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-34883 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3576 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-38459 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-2425 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-40883 usd
us-gaap Net Income Loss
NetIncomeLoss
-15878 usd
us-gaap Net Income Loss
NetIncomeLoss
-21827 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2001 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2001 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4500 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4500 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9377 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15326 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
9479 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
238 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9479 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
102 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15088 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1810 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15848 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1912 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
760 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65784 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49906 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zye30seKVvQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited level of operations during the reporting period, the Company made no material assumptions or estimates other than the assumption that the Company is a going concern and estimate with reference to amortization of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2001 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2001 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
26000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
21500 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
none-20231130_pre.xml Edgar Link unprocessable
none-20231130_cal.xml Edgar Link unprocessable
none-20231130_lab.xml Edgar Link unprocessable
none-20231130_def.xml Edgar Link unprocessable
0001683168-24-000170-index-headers.html Edgar Link pending
0001683168-24-000170-index.html Edgar Link pending
0001683168-24-000170.txt Edgar Link pending
0001683168-24-000170-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
intorio_ex3101.htm Edgar Link pending
intorio_ex3102.htm Edgar Link pending
intorio_ex3201.htm Edgar Link pending
intorio_i10q-113023.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20231130.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
intorio_i10q-113023_htm.xml Edgar Link completed